ENDP - Endo International plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.82
+0.36 (+2.89%)
As of 10:44AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close12.46
Open12.49
Bid12.93 x 800
Ask12.94 x 1400
Day's Range12.32 - 13.02
52 Week Range5.27 - 18.50
Volume1,037,064
Avg. Volume4,306,107
Market Cap2.876B
Beta (3Y Monthly)0.33
PE Ratio (TTM)N/A
EPS (TTM)-4.95
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.25
Trade prices are not sourced from all markets
  • How Is Salix Pharmaceuticals Positioned in November?
    Market Realistyesterday

    How Is Salix Pharmaceuticals Positioned in November?

    Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017, reflecting ~2% YoY growth. Xifaxan and Relistor primarily contributed to the revenue growth of Salix Pharmaceuticals in the third quarter. In the third quarter, Xifaxan and Relistor witnessed ~11% and 88% YoY organic revenue growth.

  • How Wall Street Analysts View Bausch Health in November
    Market Realist4 days ago

    How Wall Street Analysts View Bausch Health in November

    On November 13, Bausch Health stock closed at $26.63, which is a ~1.60% increase from its prior close of $26.21 on November 12, 2018. On November 13, Bausch Health stock closed at $26.63, a ~92% increase from its 52-week low of $13.86 on November 15, 2017. On October 3, 2018, Bausch Health hit its 52-week high of $28.45.

  • Managers Of This Fund Like The Outlook For Small-Cap Stocks
    Investor's Business Daily5 days ago

    Managers Of This Fund Like The Outlook For Small-Cap Stocks

    This mutual fund is focused on small-cap stocks, and the fund's managers like the outlook for small caps.

  • Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
    Investor's Business Daily7 days ago

    Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

    The best pharmaceutical stocks to buy have a commonality: Strong Composite Ratings and Relative Strength Ratings.

  • See what the IHS Markit Score report has to say about Endo International PLC.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    Endo International PLC NASDAQ/NGS:ENDP

  • Endo International’s Expense Projections for 2018
    Market Realist7 days ago

    Endo International’s Expense Projections for 2018

    On its third-quarter earnings conference call, Endo International (ENDP) raised its projection for operating expenses as a percentage of its total revenue guidance for 2018 from its previously projected range of 26.0%–27.0% to 27.0%.

  • Revenue Projections for Endo International for 2018
    Market Realist8 days ago

    Revenue Projections for Endo International for 2018

    On its third-quarter earnings conference call, Endo International (ENDP) raised its revenue guidance for 2018 from the previously projected range of $2.75 billion–$2.85 billion to $2.87 billion–$2.92 billion mainly due to its stronger-than-anticipated performance YTD (year-to-date).

  • Analysts’ Recommendations for Endo International in November
    Market Realist8 days ago

    Analysts’ Recommendations for Endo International in November

    The stock was trading 22.77% lower than its closing price of $17.08 on November 1. It closed at $13.49 on November 9, 2.27% higher than its previous closing price. Endo International reported its third-quarter earnings results on November 8.

  • BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up
    Zacks8 days ago

    BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up

    BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q3. Sales were almost in line with the consensus mark.

  • Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat
    Zacks11 days ago

    Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat

    Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.

  • See what the IHS Markit Score report has to say about Endo International PLC.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    Endo International PLC NASDAQ/NGS:ENDP

  • Investor's Business Daily12 days ago

    Endo Plans For Cellulite Drug In 2020 — Here's Why Investors Balked

    Endo International stock crashed Thursday despite beating quarterly expectations as the generic drugmaker reportedly plans to launch its cellulite treatment in 2020.

  • Thomson Reuters StreetEvents12 days ago

    Edited Transcript of ENDP earnings conference call or presentation 8-Nov-18 1:00pm GMT

    Q3 2018 Endo International PLC Earnings Call

  • Here's Why Endo International Fell as Much as 18.9% Today
    Motley Fool12 days ago

    Here's Why Endo International Fell as Much as 18.9% Today

    The struggling drug company reported third-quarter 2018 operating results.

  • Endo International plc (ENDP) Q3 2018 Earnings Conference Call Transcript
    Motley Fool12 days ago

    Endo International plc (ENDP) Q3 2018 Earnings Conference Call Transcript

    ENDP earnings call for the period ending September 30, 2018.

  • Reuters12 days ago

    Endo targets 2020 for launch of cellulite treatment

    Endo International Plc said on Thursday it expects to launch its treatment for cellulite in the second half of 2020, a day after the company announced results from two late-stage trials testing the drug. The generic drugmaker, which beat third-quarter revenue and profit estimates, has pushed into other segments of its business, such as medical aesthetics, to cushion the impact of large retail pharmacies gaining more negotiating power for generics pricing.

  • Endo International (ENDP) Q3 Earnings and Revenues Surpass Estimates
    Zacks12 days ago

    Endo International (ENDP) Q3 Earnings and Revenues Surpass Estimates

    Endo (ENDP) delivered earnings and revenue surprises of 20.34% and 6.96%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press12 days ago

    Endo: 3Q Earnings Snapshot

    On a per-share basis, the Dublin-based company said it had a loss of 77 cents. Earnings, adjusted for amortization costs and asset impairment costs, came to 71 cents per share. The results exceeded Wall ...

  • MarketWatch12 days ago

    Endo stock rises 6% after Q3 beats and upbeat 2018 guidance

    Endo International PLC shares rose 6% in Thursday premarket trade after the company reported third-quarter adjusted profit and revenue beats and upbeat 2018 guidance. The company reported a net loss of $173.2 million, or a loss of 77 cents per share, after a loss of $96.7 million, or a loss of 43 cents per share in the year-earlier period. Endo said its adjusted earnings-per-share from continuing operations were 71 cents, above the FactSet consensus of 59 cents. Revenue declined to $745.5 million from $786.9 million in the year-earlier period, above the FactSet consensus of $694.9 million. The latest results reflect Endo's voluntary market withdrawal of the opioid pain medication Opana ER (notably, at the Food and Drug Administration's request), the company said, along with other factors like competitive pressures and discontinuations of U.S. generic drugs. Growth in the quarter, meanwhile, came from the company's launch of the antibiotic ertapenem for injection, an authorized generic for the brand-name of the antibiotic, Merck's Invanz, and continued growth in its U.S. brand-name sterile injectables products. Endo now expects 2018 revenue of $2.87 billion to $2.92 billion, above the FactSet consensus of $2.81 billion, and adjusted EPS from continuing operations of between $2.65 and $2.75, above the FactSet consensus of $2.60. Company shares have declined 1.2% over the last three months, compared with a 1.5% decline in the S&P 500 and a 2.3% rise in the Dow Jones Industrial Average .

  • PR Newswire12 days ago

    Endo Reports Third-Quarter 2018 Financial Results

    DUBLIN , Nov. 8, 2018 /PRNewswire/ --  Third-quarter 2018 revenues of $745 million compared to third-quarter 2017 revenues of $787 million Third-quarter 2018 XIAFLEX ® franchise revenues increased 22 percent ...

  • Benzinga13 days ago

    Q3 Earnings Preview For Endo

    On Thursday, Nov. 8, Endo  (NASDAQ: ENDP ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue Endo  EPS is ...

  • Endo posts positive results from experimental cellulite treatment
    American City Business Journals13 days ago

    Endo posts positive results from experimental cellulite treatment

    Endo's new drug candidate for treating cellulite showed "statistically signifiant" improvement in skin appearance in two phase-III clinical trials

  • Endo Announces Positive Results from Phase 3 Studies of Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
    PR Newswire13 days ago

    Endo Announces Positive Results from Phase 3 Studies of Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite

    Both RELEASE-1 and RELEASE-2 Studies Demonstrated Highly Statistically Significant Results (P=0.006 and P=0.002 respectively) on Efficacy Endpoints DUBLIN , Nov. 7, 2018 /PRNewswire/ --   Endo International ...

  • What's in the Cards for BioSpecifics (BSTC) in Q3 Earnings?
    Zacks14 days ago

    What's in the Cards for BioSpecifics (BSTC) in Q3 Earnings?

    On BioSpecifics' (BSTC) Q3 conference call, investor focus will be on its progress with the development of CCH for treating uterine fibroids.

  • See what the IHS Markit Score report has to say about Endo International PLC.
    Markit14 days ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    Endo International PLC NASDAQ/NGS:ENDP